Literature DB >> 8805632

High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis.

T Marth1, W Strober, B L Kelsall.   

Abstract

The immune response to oral Ag administration, including the development of oral tolerance, was explored with the use of OVA TCR-transgenic mice. Feeding high doses of OVA enhanced IFN-gamma production in the Peyer's patches, but induced tolerance in the peripheral lymphoid tissues marked by suppressed proliferative and cytokine responses. Systemic administration of Abs to IL-12 (anti-IL-12) simultaneous with Ag feeding modestly enhanced the degree of tolerance in the peripheral lymphoid tissues, as shown by increased suppression of proliferative responses after in vitro restimulation, and secondary responses in the popliteal lymph nodes following in vivo challenge and in vitro restimulation. Systemic anti-IL-12 treatment was associated with augmented TGF-beta production and T cell apoptosis in both Peyer's patches and peripheral lymphoid tissues. Cell mixing studies and proliferation assays in the presence of anti-TGF-beta provided evidence that the increased suppression of responses induced by anti-IL-12 was due primarily to the secretion of TGF-beta. These findings suggest that IL-12 negatively regulates two of the main mechanisms of oral tolerance, TGF-beta production and clonal deletion via apoptosis. in addition, they suggest that the combination of oral Ag feeding and systemic anti-IL-12 administration may be of benefit in the treatment of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805632

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes.

Authors:  B S Lundin; M R Karlsson; L A Svensson; L A Hanson; U I Dahlgren; E Telemo
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance.

Authors:  K S Barone; B Herms; L Karlosky; S Murray; J Qualls
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 3.  Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Toshiro Fukui
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

4.  Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Authors:  Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 5.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

7.  Role of CTLA-4, IL-18 and IL-10 on the Induction of Low Dose Oral Tolerance.

Authors:  Kathleen Siobhan Barone; Rachael Burns; Stephanie Horton; Armando Retana; Lindsey Jackson Meredith Wall; Tifany Nolan
Journal:  J Ky Acad Sci       Date:  2008-03-01

Review 8.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

9.  TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis.

Authors:  B Del Zotto; G Mumolo; A M Pronio; C Montesani; R Tersigni; M Boirivant
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 10.  Tolerance to noninherited maternal antigens in mice and humans.

Authors:  Partha Dutta; William J Burlingham
Journal:  Curr Opin Organ Transplant       Date:  2009-08       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.